Latest T-Cell Clinical Trial Opens for Mesothelioma Patients

Research & Clinical Trials
Reading Time: 4 mins
Publication Date: 10/08/2020
Fact Checked
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Reviewed

Asbestos.com is the nation’s most trusted mesothelioma resource

The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.

Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.

More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.

About The Mesothelioma Center at Asbestos.com

  • Assisting mesothelioma patients and their loved ones since 2006.
  • Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed mesothelioma and support organization.
Learn More About Us

Testimonials

"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."
Lashawn
Mesothelioma patient’s daughter
  • Google Review Rating
  • BBB Review Rating

How to Cite Asbestos.com’s Article

APA

Povtak, T. (2021, March 11). Latest T-Cell Clinical Trial Opens for Mesothelioma Patients. Asbestos.com. Retrieved December 3, 2022, from https://www.asbestos.com/news/2020/10/08/t-cell-trial-pleural-mesothelioma/

MLA

Povtak, Tim. "Latest T-Cell Clinical Trial Opens for Mesothelioma Patients." Asbestos.com, 11 Mar 2021, https://www.asbestos.com/news/2020/10/08/t-cell-trial-pleural-mesothelioma/.

Chicago

Povtak, Tim. "Latest T-Cell Clinical Trial Opens for Mesothelioma Patients." Asbestos.com. Last modified March 11, 2021. https://www.asbestos.com/news/2020/10/08/t-cell-trial-pleural-mesothelioma/.

T cells attacking cancer cells

Memorial Sloan Kettering Cancer Center in New York City has begun recruiting patients with pleural mesothelioma for its latest — and potentially most promising — clinical trial involving T-cell therapy.

The novel study stems from the U.S. Food and Drug Administration’s recent Investigational Drug Application approval of ATA2271, a chimeric antigen receptor known as CAR T-cell therapy.

This latest therapy will be tested in a phase I, dose-escalation clinical trial. It will involve the removal and genetic modification of a patient’s T cells, a type of white blood cell, that will be separated in the laboratory through a process known as leukapheresis.

The reprograming will target mesothelin, an antigen highly expressed on mesothelioma cells and other cancers. ATA2271 is designed specifically for treatment of solid tumors.

Until recently, various T-cell therapies had been effective only when treating blood cancers such as lymphoma and leukemia. Memorial Sloan Kettering has played a major role in changing that perception.

Mesothelioma Study Builds on Prior Clinical Trial

The ATA2271 therapy is expected to advance the success already being seen in an ongoing CAR T-cell phase II clinical trial at Memorial Sloan Kettering.

“We’ve taken what we learned earlier and used the knowledge to make this latest therapy more powerful, safer and more important,” Dr. Prasad Adusumilli, thoracic surgeon and scientist at Memorial Sloan Kettering, told The Mesothelioma Center at Asbestos.com. “This is not one step forward. This is taking three steps forward.”

The most significant advancements over earlier applications should be longer CAR T-cell persistence and activity, and an automatic internal checkpoint inhibitor. This would eliminate the need for drugs such as pembrolizumab, known by the brand name Keytruda, which is used in the earlier study.

Returns from the previous trial have been positive with a 72% response rate and more than half the patients experiencing significant reduction in tumor burden. The T-cell modifications in the laboratory proved safe and well tolerated. It also targets mesothelin.

Memorial Sloan Kettering also is studying the use of TC-210 in a phase I/II clinical trial with the National Cancer Institute, Sarah Cannon Research Institute in Nashville, University of Texas MD Anderson Cancer Center in Houston and Penn Medicine Abramson Cancer Center in Philadelphia.

Adusumilli Advancing Mesothelioma Treatment

The FDA’s most recent approval was based on preclinical research from the laboratory of Adusumilli, who is the co-director of the mesothelioma program at Memorial Sloan Kettering. He presented his work at the 2020 American Association for Cancer Research annual meeting.

Dr. Michel Sadelain, director of the Center for Cell Engineering at Memorial Sloan Kettering, played a major role in developing the latest technology. The work was a collaborative effort with Atara Biotherapeutics, a T-cell immunotherapy company based in San Francisco that is sponsoring the trial.

Medical oncologist Dr. Roisin O’Cearbhaill is principal investigator of the trial that was first posted Oct. 6. She is hoping to enroll 30 patients. Cohorts of three patients will be treated at each dose level until the optimal level is reached.

Patients in the trial also will be given cyclophosphamide, a preconditioning chemotherapy, two to seven days before receiving the CAR T-cell infusion.

Adusumilli’s preclinical testing of the novel therapy included:

  • More effective destruction of cancer cells
  • Improved CAR T-cell persistence
  • Decreased cell exhaustion

Adusumilli, known as an international leader in the field, believes that CAR T-cell therapy will eventually be part of future standard-of-care for pleural mesothelioma, a rare but aggressive cancer with no definitive cure.

“For a phase I clinical trial, we observed convincing safety and efficacy data,” Adusumilli said. “The new trial is built upon our clinical and laboratory observations and is promising.”

Connect with a Mesothelioma Doctor
Find a Top Specialist Near You